Sarcomas | Specialty

The sarcomas/tgct condition center is a comprehensive resource for clinical news and expert insights on sarcomas/tgct. Read more at OncLive.

Pexidartinib Shows Long-Term Safety and Efficacy in Symptomatic TGCT

July 9th 2025

Pexidartinib generated long-term responses in patients with symptomatic tenosynovial giant cell tumors.

Denosumab Biosimilar Earns European Approval in Advanced Malignancies Involving the Bone and Giant Cell Tumors of the Bone

July 2nd 2025

Denbrayce was approved in Europe for the treatment of skeletal-related events in advanced malignancies involving the bone and giant cell tumor of the bone.

Dr Vasquez on the Rationale for Investigating NAMPT Inhibition in Rhabdomyosarcoma

June 30th 2025

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

Tigilanol Tiglate Shows Early Efficacy in Soft Tissue Sarcomas

June 27th 2025

Data from the first stage of a phase 2a study suggest that tigilanol tiglate reduced tumor volume in patients with soft tissue sarcoma.

Dr Randall on the Evolving Role of Surgical Management in Low-Grade Chondrosarcoma

June 27th 2025

R. Lor Randall, MD, FACS discusses the evolving role of surgical management in patients with low-grade chondrosarcoma.

THE001 Plus Regional Hyperthermia Shows Early Efficacy, Safety in Pretreated Soft Tissue Sarcoma

June 24th 2025

THE001 plus regional hyperthermia was safe and led to responses in patients with heavily pretreated soft tissue sarcoma.

Nirogacestat Awaits Review Following Positive CHMP Opinion for Desmoid Tumors

June 20th 2025

The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.

Dr D'Amato on the Implications of Data With Olaparib Plus Temozolomide in Advanced Uterine Leomyosarcoma

June 16th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma

June 11th 2025

Olaparib plus temozolomide was not superior to pazopanib or trabectedin for the treatment of patients with advanced uterine leiomyosarcoma.

China’s Center for Drug Evaluation Accepts MAA for Pimicotinib in TGCT

June 10th 2025

The Center for Drug Evaluation of the Chinese NMPA has accepted the marketing authorization application for pimicotinib in patients with TGCT.

OS Therapies Seeks RMAT Designation for OST-HER2 in Pediatric Lung-Metastatic Osteosarcoma

June 9th 2025

OS Therapies submits a RMAT designation request for OST-HER2 for the treatment of patients with pediatric lung-metastatic osteosarcoma.

Annamycin Drives Clinical Benefit in Soft Tissue Sarcoma Lung Metastases

June 4th 2025

Annamycin yielded a 59.4% CBR and a median OS of 13.5 months in soft tissue sarcoma lung metastases.

CHMP Shares Positive Opinion for Denosumab Biosimilars for Osteoporosis and Skeletal-Related Cancer Complications

June 3rd 2025

The European Medicines Agency's CHMP has recommended the use of denosumab biosimilars referencing Prolia and Xgeva in all reference product indications.

Dr Randall on Consensus Developed at The Annual Birmingham Orthopedic Oncology Meeting

May 27th 2025

R. Lor Randall, MD, FASCO, discusses key areas of consensus discussed at the Annual Birmingham Orthopedic Oncology Meeting.

Eftilagimod Alfa/Radiotherapy/Pembrolizumab Yields Favorable Hyalinization/Fibrosis in Soft Tissue Sarcoma

May 27th 2025

Eftilagimod alfa plus radiotherapy and pembrolizumab improved tumor hyalinization/fibrosis rates vs radiotherapy alone in resectable soft tissue sarcoma.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25th 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

Dr Vasquez on NAPRT as a Potential Biomarker for NAMPT Inhibition in Pediatric Rhabdomyosarcoma

May 22nd 2025

Juan Vasquez, MD, discusses how loss of NAPRT expression may serve as a biomarker for antitumor activity with NAMPT inhibition in rhabdomyosarcoma.

Dr Pimenta on Ongoing Therapeutic Challenges in Soft Tissue Sarcomas

May 16th 2025

Erica Maria Pimenta, MD, discusses ongoing therapeutic and translational challenges in the treatment of soft tissue sarcomas.

THE001 Receives Orphan Drug Designation for Soft Tissue Sarcoma

May 12th 2025

THE001, a doxorubicin-encapsulating thermosensitive liposome therapy, has been granted FDA orphan drug designation for soft tissue sarcoma.

x